Guideline

Pediatric gastrointestinal : European Society of Gastro- intestinal Endoscopy (ESGE) and European Society for Paediatric and Nutrition (ESPGHAN) Guideline Executive summary

Authors 19 Division of Gastroenterology and Hepatology, Department of Andrea Tringali1,*, Mike Thomson2,*, Jean-Marc Dumonceau3,Marta Internal III, Medical University of Vienna, Vienna, Tavares4, Merit M. Tabbers5,RaoulFurlano6, Manon Spaander7, Austria Cesare Hassan8, Christos Tzvinikos9, Hanneke Ijsselstijn10,Jérôme 20 Department of Gastroenterology, Leeds Teaching Viala11,LuigiDall’Oglio12,MarcBenninga5,RokOrel13,Yvan NHSTrust,Leeds,UK Vandenplas4,RadanKeil15, Claudio Romano16, Eva Brownstone17, 21 Department for Pediatric and Gastroenterology, Štěpán Hlava15,PatrickGerner18, Werner Dolak19,RosarioLandi1, Medical University of Vienna, Austria g n Wolf Dietrich Huber19, Simon Everett20,AndreasVecsei21,Lars 22 GI Endoscopy Unit, OUS, Rikshospitalet University , Aabakken22, Jorge Amil-Dias4, Alessandro Zambelli23 Oslo, Norway

endu 23 Gastroenterology and Digestive Endoscopy Unit, Ospedale w Institutions Nuovo Robbiani di Soresina, Italy e r

V 1 Digestive Endoscopy Unit, Catholic University, Rome, Italy 2 International Academy for Paediatric Endoscopy Training, Bibliography

hen Sheffield Children’s Hospital, Weston Bank, Sheffield, UK DOI http://dx.doi.org/10.1055/s-0042-111002 3 Gedyt Endoscopy Center, Buenos Aires, Argentina Published online: 12.9.2016 | Endoscopy 2017; 49: 83–91 4 Department of Pediatric Gastroenterology, Centro Hospitalar © Georg Thieme Verlag KG Stuttgart · New York sönli c de São João, Porto, Portugal ISSN 0013-726X 5 Department of Pediatric Gastroenterology, Emma Children’s

ur pe r Hospital, Academic Medical Center, Amsterdam, The This Executive summary and the full Guideline are published Netherlands simultaneously in Endoscopy and the Journal of Pediatric k z 6 Department of Pediatric Gastroenterology and Nutrition, Gastroenterology and Nutrition, respectively. Copyright 2016 u c ’ d r University Children s Hospital Basel, Switzerland © Georg Thieme Verlag KG and © Wolters Kluwer. r 7 Department of Gastroenterology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands Corresponding author 8 Department of Gastroenterology, Nuovo Regina Margherita Andrea Tringali, MD PhD, Digestive Endoscopy Unit, Catholic Hospital, Rome, Italy University, Largo A. Gemelli 8, 00168 Rome, Italy, her Sonde 9 Department of Pediatric Gastroenterology, Alder Hey Children’s Fax: +39-6-30157220, Hospital, Liverpool, UK [email protected] 10 Department of Pediatric and Intensive Care, Erasmus ronis c t MC, Sophia Children’s Hospital, Rotterdam, The Netherlands

k ABSTRACT l e 11 Department of Pediatric Gastroenterology, Robert-Debré This Executive summary of the Guideline on pediatric gastrointesti- E Hospital, Paris, France nal endoscopy from the European Society of Gastrointestinal Endos- 12 Digestive Endoscopy and Surgery Unit, Bambino Gesù copy (ESGE) and the European Society for Paediatric Gastroenterol- ’ Children s Hospital-IRCCS, Rome, Italy ogy Hepatology and Nutrition (ESPGHAN) refers to infants, children, 13 Department of Gastroenterology, Hepatology and Nutrition, and adolescents aged 0– 18 years. The areas covered include: indi- ’ University Children s Hospital Ljubljana, Slovenia cations for diagnostic and therapeutic esophagogastroduodeno- 14 Pediatric Gastroenterology, UZ Brussel, Vrije Universiteit scopy and ileocolonoscopy; endoscopy for foreign body ingestion; Brussel, Brussels, Belgium endoscopic management of corrosive ingestion and stricture/ste- 15 Department of Gastroenterology, Motol University Hospital, nosis; upper and lower gastrointestinal bleeding; endoscopic retro- Prague, Czech Republic grade cholangiopancreatography, and endoscopic ultrasonography. 16 Department of , University of Messina, Italy Percutaneous endoscopic gastrostomy and endoscopy specific to 17 IV Medical Department, Rudofstiftung Hospital, Vienna, inflammatory bowel disease (IBD) have been dealt with in other Austria Guidelines and are therefore not mentioned in this Guideline. Train- ’ 18 Department of General Pediatrics, Children s Hospital Freiburg ing and ongoing skill maintenance will be addressed in an imminent University, Freiburg, Germany sister publication.

* Co-First authors

Tringali Andrea et al. Pediatric gastrointestinal endoscopy: … Endoscopy 2017; 49: 83–91 83 Guideline

endoscopist. This Guideline tries to address this issue of endos- ABBREVIATIONS copist skills, and certainly the upcoming ESPGHAN/ESGE Guide- AUGIB acute upper gastrointestinal bleeding line on training in pediatric endoscopy will help in this respect. CT computed tomography How, where, and when endoscopy may be employed in pedia- EGD esophagogastroduodenoscopy tric management is particularly important in the areas of GI ERCP endoscopic retrograde cholangiopancreato- bleeding and endoscopic retrograde cholangiopancreatogra- graphy phy/endoscopic ultrasound (ERCP/EUS). ESGE European Society of Gastrointestinal Endoscopy This undertaking is the first joint endoscopy review between ESPGHAN European Society for Paediatric Gastroenterology pediatric and adult endoscopy representative groups in Europe. Hepatology and Nutrition Our aspiration is that this Guideline may lead to a degree of EBUS endobronchial ultrasound standardization in the utility and practice of endoscopic ap- EUS endoscopic ultrasonography proaches for children, thereby contributing to excellence and FCSEMS fully covered self-expandable metal stent appropriateness of care. GI gastrointestinal Percutaneous endoscopic gastrostomy and endoscopy GRADE Grading of Recommendations Assessment, specific to inflammatory bowel disease (IBD) have been dealt – Development and Evaluation with in other Guidelines [2 4], and are therefore not men- GVHD graft-versus-host disease tioned in the pediatric GI endoscopy Guideline. Training and on- IBD inflammatory bowel disease going skill maintenance will be addressed in an imminent sister MMC mitomycin C publication. g n NSAID non-steroidal anti-inflammatory drug RCT randomizedcontrolledtrial Methods endu TAC triamcinolone acetonide w ESGE and ESPGHAN agreed to develop a joint guideline. Two e r

V guideline leaders (A.T. for ESGE and M.T. for ESPGHAN) invited the listed authors to participate in the project. The key ques- hen Time definitions tions were prepared by the coordinating team (A.T., M.T., M. Emergent/emergency <2 hours M.T., R.F., Y.V., J.-M.D.) and then approved by the other mem-

sönli c Urgent/urgently <12 hours or <24 hours and defined in text bers. The coordinating team established task force subgroups, Early <48 hours but may be at clinician’s discretion each with its own leader, and assigned the following key topics among the task forces: esophagogastroduodenoscopy (EGD) ur pe r and ileocolonoscopy; foreign bodies; corrosive ingestion; cor- k z Introduction rosive ingestion and esophageal strictures/stenoses; GI bleed- u c Gastrointestinal (GI) endoscopy in the pediatric population has ing; endoscopic retrograde cholangiopancreatography (ERCP); d r r evolved during the last 30 years with an increasing number of and endoscopic ultrasonography (EUS). Each task force per- diagnostic and therapeutic applications. Technological im- formed a systematic literature search to prepare evidence- provements in endoscope design and endoscopic devices have based and well-balanced statements on their assigned key contributed to the evolution of pediatric endoscopy. questions. Searches were performed in PubMed and/or EMBASE her Sonde Endoscopy in the pediatric population has generally, to date, and/or Cochrane (publication date from 2000 to May 2015, or been performed by both non-pediatric endoscopists in con- before if strictly needed), including as a minimum the key

ronis c junction with pediatricians and by pediatric endoscopists in words “pediatric” and “endoscopy.” All articles studying the ap- t k specialized centers. plication of diagnostic and therapeutic endoscopy in the pedia- l e

E This document is the Executive summary of the Guideline on tric age range were selected by title or abstract. The results of pediatric GI endoscopy [1] commissioned by the European So- the relevant publications were summarized in literature tables ciety for Paediatric Gastroenterology Hepatology and Nutrition and graded by the level of evidence and strength of recommen- (ESPGHAN) and the European Society of Gastrointestinal En- dation according to the Grading of Recommendations Assess- doscopy (ESGE). The aims of the evidence-based and consen- ment, Development and Evaluation (GRADE) system [5,6]. sus-based Guideline are to provide a comprehensive review of Each task force proposed statements on their assigned key the clinical indications and timing of diagnostic and therapeutic questions which were discussed and voted on during the plen- endoscopy in pediatric patients. It is not meant to be a compre- ary meeting held in February 2015 in Munich. In November hensive overview of a patient’s care, and investigation/ 2015, a draft prepared by A.T., C.H. and M.T. was sent to all for each area will, of course, involve the clinician’s discretion re- group members. After agreement from all the authors on a fi- garding the place of endoscopy in overall management, en- nal version, the manuscript was reviewed by two members of compassing, as it must, complementary non-endoscopic ap- the ESGE Governing Board, ESGE individual members and the proaches. The role of endoscopy in the overall management ESPGHAN Council. will depend on a number of factors, including but not limited The manuscript was then submitted to the Journal of Pedia- to the specific clinical features, the availability/appropriateness tric Gastroenterology and Nutrition for publication in full length of non-endoscopic approaches, and the available skills of the and to Endoscopy for publication of the Executive summary.

84 Tringali Andrea et al. Pediatric gastrointestinal endoscopy:… Endoscopy 2017; 49: 83–91 Both the Guideline and Executive summary were issued in ▶ Table1 Typical diagnostic and therapeutic indications, non-indica- 2016 and will be considered for review and update in 2021 or tions, and contraindications for esophagogastroduodenoscopy (EGD) sooner if new and relevant evidence becomes available. Any up- in pediatric patients. dates to the Guideline or Executive summary in the interim will Diagnostic indications Weight loss, failure to thrive be noted on the ESGE and ESPGHAN websites: http://www. esge.com/esge-guidelines.html and http://www.espghan.org/ Unexplained

guidelines/ Abdominal pain with suspicion of an organic disease

Recommendations Dysphagia or odynophagia

Esophagogastroduodenoscopy (EGD) Caustic ingestion

ESGE/ESPGHAN suggest diagnostic and therapeutic EGD for Recurrent vomiting with unknown the indications listed in ▶Table1 and ▶ Table 2,respectively. cause (Weak recommendation, low quality evidence.) Hematemesis ESGE/ESPGHAN do not suggest EGD in the case of uncom- plicated gastroesophageal reflux, functional gastrointestinal Hematochezia disorders, or for diagnosing perforation. (Weak recommenda- Unexplained chronic diarrhea tion, low quality evidence.) Suspicion of graft versus host disease ESGE/ESPGHAN suggest routine tissue sampling even in the g Chronic GERD, to exclude other dis- n absence of visible endoscopic abnormalities in all children un- eases, or surveillance of Barrett’s dergoing EGD. (Weak recommendation, low quality evidence.) esophagus

endu ESGE/ESPGHAN suggest using ESPGHAN guidelines (on eo- w sinophilic esophagitis, Helicobacter pylori, celiac disease, and in- Therapeutic indications Percutaneous endoscopic gastrostomy e r (re)placement

V flammatory bowel disease [IBD]) for precise indications and preferred sites for biopsy during EGD in children suspected of Duodenal tube placement hen ▶ aspecificdisease( Table3). (Weak recommendation, low Foreign body removal quality evidence.) Food impaction sönli c ESGE/ESPGHAN suggest performing EGD in children under general or, only if general anesthesia is not available, Hemostasis under deep sedation in a carefully monitored environment.

ur pe r Percutaneous jejunostomy placement (Weak recommendation, low quality evidence.) k z ESGE/ESPGHAN suggest performing EGD in a child-friendly Esophageal varices u c setting with appropriate equipment and by an endoscopist Dilation of esophageal or upper GI d r r trained in pediatric gastroenterology. (Weak recommendation, strictures low quality evidence.) Perforation ESGE/ESPGHAN suggest that when adult endoscopists per- Achalasia form pediatric procedures, collaboration between adult gastro- her Sonde enterologists and pediatricians is always warranted. (Weak re-

commendation, low quality evidence.) Non-indications Uncomplicated GERD

ronis c ESGE/ESPGHAN suggest that the choice of gastroscope type t Functional GI disorders k should depend on the child’sweightandage(▶ Table4). (Weak l e

E recommendation, low quality evidence.) Contraindications To diagnose perforation

Ileocolonoscopy GERD, gastroesophageal reflux disease; GI, gastrointestinal ESGE/ESPGHAN suggest ileocolonoscopy for the diagnostic and therapeutic indications listed in ▶ Table 5. (Weak recom- ment and by an endoscopist trained in pediatric gastroenterol- mendation, low quality evidence.) ogy. (Weak recommendation, low quality evidence.) ESGE/ESPGHAN suggest against ileocolonoscopy in the case ESGE/ESPGHAN suggest that when non-pediatric endosco- of toxic megacolon, recent colonic perforation (<28 days), re- pists perform pediatric procedures in older children, collabora- cent intestinal resection (<7 days), or functional GI disorders. tion with a pediatrician is always warranted. (Weak recommen- (Weak recommendation, low quality evidence.) dation, low quality evidence.) ESGE/ESPGHAN suggest performing ileocolonoscopy in chil- ESGE/ESPGHAN suggest that the choice of colonoscope dren under general anesthesia or, only if general anesthesia is type should depend on the child’sweightandage(▶Table4). not available, under deep sedation in a carefully monitored en- (Weak recommendation, low quality evidence.) vironment. (Weak recommendation, low quality evidence.) ESGE/ESPGHAN suggest that ileocolonoscopy should be performed in a child-friendly setting with appropriate equip-

Tringali Andrea et al. Pediatric gastrointestinal endoscopy: … Endoscopy 2017; 49: 83–91 85 Guideline

Bowel preparation for ileocolonoscopy in children ▶ Table2 Diagnostic indications for esophagogastroduodenoscopy (EGD) in pediatric patients: symptoms/signs according to suspected ESGE/ESPGHAN recommend low-volume preparation for bowel disease. cleansing in children, using either polyethylene glycol plus as- corbate or picosulphate plus magnesium citrate/Senokot. Symptoms/signs Suspicion of: (Strong recommendation, high quality evidence.) Weight loss, failure to thrive, Celiac disease or IBD, giardiasis, ESGE/ESPGHAN recommend against the use of sodium chronic diarrhea, malabsorption, allergic enterocolitis, bleeding phosphate for bowel cleansing. (Strong recommendation, high anemia, abdominal pain with lesions, graft versus host disease quality evidence.) suspicionofanorganicdisease

Dysphagia, odynophagia, chest Foreign body ingestion, food Ileocolonoscopy in children: biopsy, carbon dioxide pain, feeding difficulty impaction, caustic ingestion or insufflation, ileal , polypectomy technique eosinophilic esophagitis ESGE/ESPGHAN suggest routine biopsy even in the absence of Hematemesis, hematochezia, Polyps, angiodysplasia, arterio- visible endoscopic abnormalities in all children with suspected melena venous malformations, peptic ul- IBD undergoing ileocolonoscopy. (Weak recommendation, low cer with or without Helicobacter quality evidence.) pylori , less common conditions such as duplication ESGE/ESPGHAN suggest using ESPGHAN guidelines relating cysts to ulcerative colitis and the revised Porto criteria for diagnosis of IBD for precise indications and preferred sites to biopsy. Family history of polyposis Polyps (diagnostic and syndromes surveillance) (Weak recommendation, low quality evidence.) g

n ESGE/ESPGHAN did not find any evidence to recommend IBD, inflammatory bowel disease. against or for the use of routine carbon dioxide insufflation dur-

endu ing ileocolonoscopy in children. Pain seems to be rare and mild w after ileocolonoscopy in children. (Weak recommendation, low e r ▶ Table3 Indication and site for tissue sampling during upper and

V quality evidence.) lower endoscopy in pediatric patients. ESGE/ESPGHAN suggest that ileal intubation should be at- hen Indication Tissue samples: sites and numbers tempted in symptomatic children with abdominal pain, intes- tinal bleeding, diarrhea, or with any suspicion of IBD. (Weak re- Eosinophilic At least 3 biopsies should be taken, one from sönli c esophagitis proximal mid and distal esophagus, regardless commendation, low quality evidence.) of the endoscopic appearance of the esopha- ESGE/ESPGHAN suggest removal of very small polyps gus (< 3 mm) by cold biopsy forceps and 3– 8mmpolypsbyhotor ur pe r cold snaring. Cold snaring is advisable in the right colon where Helicobacter pylori 2 biopsies from both the antrum and the k z infection corpus (± fundus) the perforation risk is higher. For polyps>8mm, hot snaring is u c suggested. (Weak recommendation, low quality evidence.) d r

r Celiac disease At least 1 biopsy from the duodenal bulb and at least 4 biopsies from the second or third Foreign body ingestion portion of the duodenum ESGE/ESPGHAN recommend an early referral to the emergency IBD Multiple biopsies (2 or more per section) from room and X-ray evaluation in all patients with suspected foreign all sections of the visualized GI tract, even in her Sonde the absence of macroscopic lesions body ingestion even if asymptomatic. Biplane radiographs should be obtained of the neck, chest, abdomen, and pelvis if IBD, inflammatory bowel disease; GI, gastrointestinal. ronis c t k l e

E ▶ Table4 Types of endoscopes used in pediatric patients according to body weight, age, and procedure.

EGD Colonoscopy ERCP EUS

Weight or age

<10kgor<1year ≤ 6mmgastroscope ≤ 6mm gastroscope, stand- 7.5mm duodenoscope Miniprobe or 7.4mm preferred. ard adult gastroscope, or EBUS scope. Consider standard adult pediatric colonoscope. gastroscope if endotherapy required.

≥ 10kg or ≥ 1 year Standard adult gastroscope. Pediatric or adult Therapeutic duodenoscope Miniprobe or 7.4mm Therapeutic gastroscope if colonoscope. (4.2mm operative channel) EBUS scope. needed.

≥ 15kg or ≥ 3years –––Adult radial/linear echoendoscope

EGD, esophagogastroduodenoscopy; ERCP, endoscopic retrograde cholangiopancreatography; EUS, endoscopic ultrasonography; EBUS, endobronchial ultrasound.

86 Tringali Andrea et al. Pediatric gastrointestinal endoscopy:… Endoscopy 2017; 49: 83–91 ▶ Table5 Typical diagnostic and therapeutic indications, non-indica- pass spontaneously after 4 weeks. (Weak recommendation, low tions, and contraindications for ileocolonoscopy in pediatric patients. quality evidence.)

Diagnostic indications Unexplained anemia Sharp-pointed objects

Unexplained chronic diarrhea ESGE/ESPGHAN recommend emergent (<2 hours) removal of sharp-pointed objects located in the esophagus (all cases). Perianal lesions (fistula, abscess) (Strong recommendation, moderate quality evidence.) Rectal blood loss ESGE/ESPGHAN recommend emergent (<2 hours) removal Unexplained failure to thrive of sharp-pointed objects in the stomach or proximal duodenum even in asymptomatic children. (Strong recommendation, Suspicion of graft versus host moderate quality evidence.) disease

Rejection or complications after Batteries intestinal transplantation ESGE/ESPGHAN recommend to emergently (<2 hours) remove Radiological suspicion of ileocolonic button batteries impacted in the esophagus. (Strong recom- stenosis/stricture mendation, low quality evidence.) Polyposis syndromes ESGE/ESPGHAN suggest to remove button batteries in the stomach emergently (<2 hours) if the child is symptomatic and/or has a known or suspected anatomical in the g Therapeutic indications Polypectomy ’ n GI tract (e. g. Meckel s diverticulum), and/or has simultaneous- Dilation of ileocolonic stenosis ly swallowed a magnet. (Weak recommendation, low quality

endu evidence.) Treatment of hemorrhagic lesions w ESGE/ESPGHAN suggest that button batteries larger than e r Foreign body removal

V > 20 mm present in the stomach should be checked by radio- Reduction of sigmoidal volvulus graphy and removed if still in place after more than 48 hours. hen (Weak recommendation, low quality evidence.) ESGE/ESPGHAN recommend an urgent endoscopic removal Non-indications Functional GI disorders sönli c (< 24 hours) for single cylindrical battery ingestion when im- Constipation pacted in the esophagus and as soon as possible elsewhere in theGItractwhenthechildissymptomatic.(Strongrecommen- ur pe r dation, moderate quality evidence.) k z Contraindications Toxic megacolon ESGE/ESPGHAN suggest that a single cylindrical battery in u c thestomachcanbeobservedandthechildmonitoredasan d r Recent colonic perforation r outpatient and followed by X-ray 7– 14 days after ingestion if Recent intestinal resection (<7 days) the battery is not passed in the stool. (Weak recommendation, GI, gastrointestinal. low quality evidence.)

her Sonde Magnets indicated. Computed tomography (CT) scan can be considered ESGE/ESPGHAN recommend urgent (<24 hours) removal of all

ronis c for radiolucent foreign bodies. (Strong recommendation, mod- magnets within endoscopic reach. For those beyond endo- t k erate quality evidence.) scopic reach, close observation and surgical consultation for l e

E ESGE/ESPGHAN suggest early EGD if the foreign body is in non-progression through the GI tract is advised. (Strong re- the esophagus. (Weak recommendation, low quality evidence.) commendation, moderate quality evidence.)

Blunt foreign bodies and coins Food bolus impaction ESGE/ESPGHAN recommend removal of blunt foreign bodies ESGE/ESPGHAN recommend removal of impacted food from and coins or impacted food from the esophagus urgently (<24 the esophagus as an emergency 2 hours from the time of pres- hours), even in asymptomatic children. If the child is sympto- entation (and ideally from the time of ingestion) in case of matic an emergent (<2 hours) removal is indicated especially symptoms (drooling, neck pain). If the child is asymptomatic for button batteries. (Strong recommendation, moderate qual- an urgent (< 24 hours) removal is indicated. (Strong recom- ity evidence.) mendation, moderate quality evidence.) ESGE/ESPGHAN suggest removal of blunt foreign bodies ESGE/ESPGHAN suggest investigation for underlying pathol- from the stomach or duodenum if the child is symptomatic or ogy of the esophagus in all cases of food impaction. (Weak re- if the object is wider than 2.5cm in diameter or >6cm in commendation, low quality evidence.) length. Otherwise, blunt foreign bodies in the stomach can be followed and retrieved only if they produce symptoms or do not

Tringali Andrea et al. Pediatric gastrointestinal endoscopy: … Endoscopy 2017; 49: 83–91 87 Guideline

Drug packets for 4 weeks once the age-appropriate feeding diameter has ESGE/ESPGHAN recommend against endoscopic removal of been achieved (recurrent).” (Weak recommendation, very low drug-containing packets. (Strong recommendation, low quality level of evidence.) evidence.) ESGE/ESPGHAN suggest temporary stent placement or ap- plication of topical mitomycin C (MMC) following dilation for Equipment for removal of foreign bodies refractory esophageal stenosis in children. ESGE/ESPGHAN do ESGE/ESPGHAN suggest that flexible endoscopy is an effective not suggest the routine use of intralesional steroids for refrac- and safe procedure for removing foreign bodies from the GI tory esophageal stenosis in children. (Weak recommendation, tract, with a high success rate using retrieval nets, polypectomy low quality evidence.) snares, and rat-tooth forceps. (Weak recommendation, very In patients operated for , ESGE/ESP- low quality evidence.) GHAN suggest long-term endoscopic surveillance for Barrett’s esophagus and cancer. Frequency would be dictated by the Corrosive ingestion presence or not of dysplasia and should follow standard guide- ESGE/ESPGHAN suggest that every child that has ingested a lines already published in the literature. (Weak recommenda- corrosive substance should have a thorough follow-up, with en- tion, low quality evidence.) doscopy dictated only by symptoms, and dependent on the symptoms the timing should be within 24 hours. (Strong re- Upper and lower GI bleeding commendation, high quality evidence.) ESGE/ESPGHAN suggest that, having employed all necessary ESGE/ESPGHAN recommend that every child with a suspect- medical interventions as standard, EGD be performed very ear- g ≤ n ed caustic ingestion and symptoms/signs (any oral lesions, vo- ly ( 12 h) in acute upper GI bleeding (AUGIB) cases which re- miting, drooling, dysphagia, hematemesis, dyspnea, abdomi- quire ongoing circulatory support or where a large hematem-

endu nal pain, etc) should have an EGD in order to identify all conse- esis or melena occurs. (Weak recommendation, low quality evi- w quent digestive tract lesions. (Strong recommendation, high dence.) e r

V quality evidence.) ESGE/ESPGHAN recommend that, having employed all nec- ESGE/ESPGHAN suggest that in the case of suspected corro- essary medical interventions as standard, EGD be performed hen sive ingestion EGD is withheld if the child is asymptomatic (no very early (<12h) in AUGIB in cases with known esophageal drooling of saliva/other symptoms and no mouth lesions) and varices. (Strong recommendation, moderate quality evidence.)

sönli c that adequate follow-up is assured. (Weak recommendation, ESGE/ESPGHAN suggest that, having employed all neces- moderate quality evidence.) sary medical interventions as standard, EGD be performed ESGE/ESPGHAN recommend to have the same grade of sus- within 24 hours in AUGIB cases which require transfusion due ur pe r picion for both acidic and alkali ingestion regarding potential to hemoglobin drop below 8g/dL, where an acute drop of 2g/ k z mucosal injury. (Alkali ingestion, especially lye, is associated dL is identified, and in those who are stable but whose bleeding u c with more severe esophageal lesions and severe gastric lesions score is above a recognized threshold/validated score for prob- d r r can occur in acidic ingestion.) Stricture development has been able endoscopic intervention requirement. (Weak recommen- associated with both acidic and alkali ingestion. (Strong recom- dation, moderate quality evidence.) mendation, high quality evidence.) ESGE/ESPGHAN suggest that EGD be performed before hos- ESGE/ESPGHAN recommend high doses of intravenous dex- pital discharge in children with AUGIB and pre-existing liver dis- her Sonde amethasone (1g/1.73m2 per day) administration for a short ease or portal hypertension. (Weak recommendation, low qual- period (3 days) in IIb esophagitisaftercorrosiveingestionasa ity evidence.)

ronis c method of preventing the development of esophageal stric- ESGE/ESPGHAN do not suggest routine use of wireless cap- t k ture. There is no evidence of benefit for the use of corticoster- sule endoscopy/enteroscopy in AUGIB in children. (Weak re- l e

E oids in other grades of esophagitis (I, IIa, III). (Strong recom- commendation, moderate quality evidence.) mendation, moderate quality evidence.) ESGE/ESPGHAN suggest that urgent (24 hours) therapeutic ileocolonoscopy is not usually necessary in lower GI bleeding Benign esophageal strictures unless severe enough to cause circulatory compromise but di- ESGE/ESPGHAN recommend esophageal dilation using balloon agnostic ileocolonoscopy is needed as soon as is practical and or bougies for benign esophageal strictures only when symp- safe. (Weak recommendation, weak quality evidence.) toms occur. (Strong recommendation, low quality evidence.) ESGE/ESPGHAN suggest the following definition of a benign Endoscopic hemostasis technique for GI bleeding refractory or recurrent stricture in children: “An anatomic re- in children striction because of cicatricial luminal compromise or fibrosis ESGE/ESPGHAN recommend hemostasis of esophageal variceal that results in dysphagia in the absence of endoscopic evidence bleeding in children, using band ligation, if feasible, or sclero- of inflammation. This may occur as the result of either an inabil- therapy as an alternative. (Strong recommendation, moderate itytosuccessfullyremediatetheanatomicproblemtoobtain quality evidence.) age-appropriate feeding possibilities after a maximum of 5 dila- ESGE/ESPGHAN suggest that the treatment of peptic ulcers tion sessions (refractory) with maximal 4-week intervals, or as a and Dieulafoy’s lesion should not be carried out with epine- result of an inability to maintain a satisfactory luminal diameter phrine injection alone but in combination with thermal or me-

88 Tringali Andrea et al. Pediatric gastrointestinal endoscopy:… Endoscopy 2017; 49: 83–91 ▶ Table6 Typical indications for ERCP in pediatric patients.

Biliary Pancreatic

Diagnostic Therapeutic Diagnostic Therapeutic

Cholestasis in neonates and infants Common bile duct stones Evaluation of anomalous biliopan- creatic junction

Choledochal cyst Bile leak Recurrent acute pancreatitis (post-surgical/post-traumatic)

Primary sclerosing cholangitis Benign biliary strictures Pancreas divisum (brush cytology)

Primary sclerosing cholangitis Pancreatic duct leak (post-surgical/post-traumatic)

Malignant biliary strictures Pancreatic pseudocyst

Parasitosis (ascariasis, fascioliasis)

ERCP, endoscopic retrograde cholangiopancreatography g n

endu chanical techniques. (Weak recommendation, low quality evi- tiary care center, and with pediatric involvement. (Strong re- w dence.) commendation, moderate quality evidence.) e r

V ESGE/ESPGHAN suggest adopting general anesthesia in chil- ESGE/ESPGHAN suggest general anesthesia for ERCP in chil- dren undergoing endoscopy for GI bleeding. General anesthe- dren. Deep/conscious sedation can be considered for teenagers hen sia is recommended in the case of variceal bleeding. Deep seda- (age 12– 17 years) although general anesthesia is the preferred tion may be used in less severe bleeding in older children. choice. (Weak recommendation, low quality evidence.)

sönli c (Weak recomendation, low quality evidence.) Prophylaxis of post-ERCP pancreatitis with non-steroidal ESGE/ESPGHAN suggest using video capsule endoscopy anti-inflammatory drugs (NSAIDs) (diclofenac/indomethacin (VCE) in children in the case of suspected small-intestinal suppository) is recommended in children older than 14 years. ur pe r bleeding and in addition balloon enteroscopy for therapeutic (Strong recommendation, high quality evidence.) k z purposes. (Weak recommendation, moderate quality evi- Protection of radiosensitive organs (thyroid gland, u c dence.) breasts, gonads and eyes) is recommended together with ad- d r r justment of collimation to the smaller size of children. (Strong Endoscopic retrograde cholangiopancreatography recommendation, high quality evidence.) (ERCP) ESGE/ESPGHAN recommend the pediatric 7.5-mm duode- ESGE/ESPGHAN suggest ERCP in pediatric patients (>1-year- noscope for children weighing <10kg and that a therapeutic her Sonde old) for therapeutic purposes following diagnostic information duodenoscope can be used in those weighing ≥ 10kg. (Strong from non-invasive diagnostic modalities such as magnetic reso- recommendation, low quality evidence.)

ronis c nance cholangiopancreatography (MRCP). Diagnostic ERCP can t k be considered in selected cases where advanced non-invasive l e ▶ Table7 Typical indications for endoscopic ultrasonography in E imaging is inconclusive. (Weak recommendation, low quality evidence.) pediatric patients. ESGE/ESPGHAN recommend that therapeutic ERCP in pedia- Esophagus Stomach Duodenum Biliopancreatic tric patients (>1-year-old) is considered for diseases listed in ▶ Table 6 following diagnostic information from non-invasive Congenital Gastric Duodenal Bile duct stones esophageal duplication duplication modalities such as MRCP. Results and complication rates of stenosis ERCP in children are similar to those reported in adults. (Weak recommendation, low quality evidence.) Eosinophilic Gastric Pancreatic esophagitis varices pseudocyst ESGE/ESPGHAN suggest that diagnostic ERCP in neonates (diagnosis and ≤ and infants ( 1-year-old) with cholestatichepatobiliarydisease treatment) is considered if non-invasive investigations are not conclusive in Esophageal Pancreatic order to allow timely referral to surgery for suspected biliary duplications diseases (±FNA) atresia or to avoid unnecessary surgery if is ex- cluded. (Weak recommendation, low quality evidence.) FNA, fine-needle aspiration. ESGE/ESPGHAN recommend that ERCP in children is per- formed by an experienced endoscopist, in a high-volume ter-

Tringali Andrea et al. Pediatric gastrointestinal endoscopy: … Endoscopy 2017; 49: 83–91 89 Guideline

Endoscopic ultrasonography (EUS) M. Tav. has not participated as a clinical investigator and/or ad- visory board member and/or consultant and/or speaker for any The endobronchial ultrasound (EBUS) endoscope can be company. adapted for EUS in children with a weight below 15kg. A stand- M. Tab. has not participated as a clinical investigator and/or ad- ard linear echoendoscope should only be employed in children visory board member and/or consultant and/or speaker for any under general anesthesia, considering the stiff and potentially company. traumatic distal part. (Weak recommendation, low quality evi- R.F. has not participated as a clinical investigator and/or advi- dence.) sory board member and/or consultant and/or speaker for any ESGE/ESPGHAN suggest the use of EUS in children only in company. tertiary referral centers with experience in therapeutic endos- M.S. has not participated as a clinical investigator and/or advi- copy. Strict collaboration between adult and pediatric gastro- sory board member and/or consultant and/or speaker for any enterologists is required in the case of EUS with standard company. echoendoscopes. (Weak recommendation, low quality evi- C.H. has not participated as a clinical investigator and/or advi- dence.) sory board member and/or consultant and/or speaker for any ESGE/ESPGHAN suggest the use of radial EUS with mini- company. probes to diagnose congenital esophageal strictures (tracheo- C.T. has not participated as a clinical investigator and/or advi- bronchial remnants vs. fibromuscular stenosis subtypes). sory board member and/or consultant and/or speaker for any (Weak recommendation, very low quality evidence.) company. ESGE/ESPGHAN suggest consideration of EUS for the diag- H.I. has not participated as a clinical investigator and/or advi- g

n nosis of pancreaticobiliary diseases in children where non-inva- sory board member and/or consultant and/or speaker for any sive imaging modalities (ultrasonography, MRCP) are inconclu- company.

endu sive (▶Table7). (Weak recommendation, very low quality evi- J.V. has not participated as a clinical investigator and/or advi- w dence.) sory board member and/or consultant and/or speaker for any e r

V ESGE/ESPGHAN suggest that EUS-guided drainage of pan- company. creatic pseudocysts in children should be performed in large L.D. has not participated as a clinical investigator and/or advi- hen EUS centers with specific experience and expertise. (Weak re- sory board member and/or consultant and/or speaker for any commendation, low quality evidence.) company.

sönli c ESGE and ESPGHAN guidelines represent a consensus of best M.B. has participated as a clinical investigator and/or advisory practice based on the available evidence at the time of prepara- board member and/or consultant and/or speaker for Shire, tion. They may not apply in all situations and should be inter- Movetis, Sucampo, Norgine, Astra Zeneca, Zeria, Novolac, Sen- ur pe r preted in the light of specific clinical situations and resource sus, Danone/Nutricia and Friesland Campina.R.O. has not parti- k z availability. Further controlled clinical studies may be needed cipated as a clinical investigator and/or advisory board member u c to clarify aspects of these statements, and revision may be nec- and/or consultant and/or speaker for any company. d r r essary as new data appear. Clinical considerations may justify a R.K. has not participated as a clinical investigator and/or advi- course of action at variance to these recommendations. ESGE sory board member and/or consultant and/or speaker for any and ESPGHAN guidelines are intended to be an educational de- company. vice to provide information that may assist endoscopists in pro- C.R. has not participated as a clinical investigator and/or advi- her Sonde viding care to patients. They are not rules and should not be sory board member and/or consultant and/or speaker for any construed as establishing a legal standard of care or as encoura- company.

ronis c ging, advocating, requiring, or discouraging any particular E.B. has not participated as a clinical investigator and/or advi- t k treatment. sory board member and/or consultant and/or speaker for any l e

E company. S.H. has not participated as a clinical investigator and/or advi- Competing interests sory board member and/or consultant and/or speaker for any company. M.Th. has participated as a clinical investigator and/or advisory W.D. has not participated as a clinical investigator and/or advi- board member and/or consultant and/or speaker and/or for Da- sory board member and/or consultant and/or speaker for any none/Nutricia, Nestlé, Mead Johnson, Movetis, Jannsen, Nor- company. gine, Reckitt-Benkeiser, Cook, Olympus_KeyMed, Fujinon, W-D.H. has not participated as a clinical investigator and/or ad- Storz, Pentax and Boston-Scientific. visory board member and/or consultant and/or speaker for any A.T. has participated as a clinical investigator and/or advisory company. board member and/or consultant and/or speaker for Boston S.E. has participated as a clinical investigator and/or advisory Scientific. board member and/or consultant and/or speaker for Olympus. J-M. D. has not participated as a clinical investigator and/or ad- A.V. has not participated as a clinical investigator and/or advi- visory board member and/or consultant and/or speaker for any sory board member and/or consultant and/or speaker for any company. company.

90 Tringali Andrea et al. Pediatric gastrointestinal endoscopy:… Endoscopy 2017; 49: 83–91 L.A. has not participated as a clinical investigator and/or advi- References sory board member and/or consultant and/or speaker for any company. [1] Thomson M, Tringali A, Dumonceau JM et al. Pediatric gastrointestinal J. A-D. has participated as a clinical investigator and/or advisory endoscopy: European Society for Paediatric Gastroenterology Hepa- board member and/or consultant and/or speaker for Danone/ tology and Nutrition (ESPGHAN) and European Society of Gastroin- testinal Endoscopy (ESGE) Guidelines. J Pediatr Gastroenterol Nutr Nutricia, Astra Zeneca and Prospectos. 2016; 00: 00– 00 PAP A.Z. has not participated as a clinical investigator and/or advi- [2] Heuschkel RB, Gottrand F, Devarajan K et al. ESPGHAN position paper sory board member and/or consultant and/or speaker for any on management of percutaneous endoscopic gastrostomy in children company. and adolescents. J Pediatr Gastroenterol Nutr 2015; 60: 131– 141 [3] Koletzko S, Jones NL, Goodman KJ et al. Evidence-based guidelines from ESPGHAN and NASPGHAN for Helicobacter pylori infection in children. J Pediatr Gastroenterol Nutr 2011; 53: 230– 243 [4] Turner D, Levine A, Escher JC et al. Management of pediatric ulcera- tive colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr 2012; 55: 340– 361 [5] Guyatt GH, Oxman AD, Vist GE et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924 – 926 [6]DumonceauJM,HassanC,RiphausAetal.EuropeanSocietyofGas- trointestinal Endoscopy (ESGE) Guideline Development Policy. En- g n doscopy 2012; 44: 626– 629 endu w e r V hen sönli c ur pe r k z u c d r r her Sonde ronis c t k l e E

Tringali Andrea et al. Pediatric gastrointestinal endoscopy: … Endoscopy 2017; 49: 83–91 91